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An integrated clinicoradiological staging system for 
pulmonary sarcoidosis: a case-cohort study
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Toby M Maher, Elizabetta Renzoni, Andrew G Nicholson, David M Hansell
Summary
Background Mortality in pulmonary sarcoidosis is highly variable and a reliable prognostic algorithm for disease 
staging and for guiding management decisions is needed. The objective of this study is to derive and test a staging 
system for determining prognosis in pulmonary sarcoidosis.
Methods We identiﬁ ed the prognostic value of high-resolution computed tomography (HRCT) patterns and 
pulmonary function tests, including the composite physiological index (CPI) in patients with pulmonary sarcoidosis. 
We integrated prognostic physiological and HRCT variables to form a clinical staging algorithm predictive of mortality 
in a test cohort. The staging system was externally validated in a separate cohort by the same methods of discrimination 
used in the primary analysis and tested for clinical applicability by four test observers.
Findings The test cohort included 251 patients with pulmonary sarcoidosis in the study referred to the Sarcoidosis 
clinic at the Royal Brompton Hospital, UK, between Jan 1, 2000, and June 30, 2010. The CPI was the strongest 
predictor of mortality (HR 1·04, 95% CI 1·02–1·06, p<0·0001) in the test cohort. An optimal CPI threshold of 40 units 
was identiﬁ ed (HR 4·24, 2·84–6·33, p<0·0001). The CPI40, main pulmonary artery diameter to ascending aorta 
diameter ratio (MPAD/AAD), and an extent of ﬁ brosis threshold of 20% were combined to form a staging algorithm. 
When assessed in the validation cohort (n=252), this staging system was strikingly more predictive of mortality than 
any individual variable alone (HR 5·89, 2·68–10·08, p<0·0001). The staging system was successfully applied to the 
test and validation cohorts combined, by two radiologists and two physicians.
Interpretation A clear prognostic separation of patients with pulmonary sarcoidosis is provided by a simple staging 
system integrating the CPI and two HRCT variables.
Funding National Institute of Health Research Respiratory Disease Biomedical Unit at the Royal Brompton and 
Hareﬁ eld NHS Foundation Trust and Imperial College London.
Introduction
For most patients, pulmonary sarcoidosis is a somewhat 
benign and self-limiting disorder. Clinically occult 
disease and spontaneous remission occur in the majority 
of patients.1,2 However, for some, pulmonary sarcoidosis 
can be a chronic and debilitating disease associated with 
signiﬁ cant mortality.3,4 Although several studies have 
reported on factors that might predict prognosis in 
pulmonary sarcoidosis such as reduced forced vital 
capacity, pulmonary arterial hypertension, and the 
radiographic presence of pulmonary ﬁ brosis, attempts 
to devise a reliable prognostic algorithm for pulmonary 
sarcoidosis have been largely unsuccessful,5–13 and this 
has impeded the development of consensus management 
and treatment recommendations. A major barrier to this 
speciﬁ c research eﬀ ort is that mortality due to pulmonary 
sarcoidosis in unselected populations is too low for the 
empowerment of survival analyses. Referral centre 
populations have a higher than expected mortality than 
that in unselected populations of patients with pul-
monary sarcoidosis.14,15 Therefore, referral centres 
provide an enriched population ideal for deriving 
prognostic methods, using mortality as an appropriate 
primary endpoint.
Pulmonary ﬁ brosis and pulmonary arterial hyper-
tension are two important causes of death in patients 
with pulmonary sarcoidosis.5,12,13,16–18 Pulmonary arterial 
hypertension is a substantial issue regardless of whether 
there is ﬁ brosis16—more than 70% of patients with 
pulmonary sarcoidosis awaiting lung transplantation 
have substantial pulmonary arterial hypertension,19 
which is present in almost half of patients with 
pulmonary sarcoidosis with dyspnoea (out of proportion 
to their pulmonary function abnormalities).20
In idiopathic pulmonary ﬁ brosis, Wells and col-
leagues21 devised the composite physiological index 
(CPI), which is a weighted index of pulmonary function 
variables that correlates with extent of interstitial disease 
on high-resolution computed tomography (HRCT). CPI 
was a stronger predictor of mortality than any individual 
lung function variable.21 Pulmonary arterial hyper-
tension is a frequent complication in idiopathic 
pulmonary ﬁ brosis and an important cause of mortality 
in these patients.22 The prognostic strength of the CPI in 
the setting of idiopathic pulmonary ﬁ brosis might be 
explained by its incorporation of diﬀ using capacity of 
carbon monoxide (DLCO), which might confer in-
creased sensitivity to concurrent pulmonary arterial 
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hypertension, while at the same time capturing the 
prognostic eﬀ ect of interstitial disease. Following from 
this ﬁ nding, the CPI could be postulated to also be 
useful in pulmonary sarcoidosis for the identiﬁ cation of 
patients with a poor prognosis.
The CPI has not been studied in sarcoidosis, thus the 
aim of our study was to assess the prognostic strength of 
the CPI in a large cohort of patients with pulmonary 
sarcoidosis. Additionally, we explored whether the CPI 
and HRCT variables could be integrated to form a clinical 
staging system for identifying patients at high and low 
risk of mortality.
Methods
Patients and study design
In this case-cohort study, we clinically deﬁ ned and did all 
pulmonary function tests and HRCTs in accordance with 
local protocols. For the purposes of a retrospective 
examination of these data, the institutional ethics review 
board waived informed patient consent.
We identiﬁ ed consecutive outpatients referred to the 
Sarcoidosis clinic at the Royal Brompton Hospital. We 
only included patients with a diagnosis of pulmonary 
sarcoidosis, synthesised from clinical, radiological, and 
pathological data and an HRCT within 90 days of 
baseline pulmonary function tests in the study 
population. Exclusion criteria were: diagnosis not 
conﬁ rmed at multidisciplinary review; no HRCT 
available within 90 days of baseline pulmonary function 
tests; and no HRCT or pulmonary function test 
evidence of pulmonary involvement. To exclude 
patients for whom a diagnosis of chronic hyper-
sensitivity pneumonitis might have been possible, all 
patients with HRCT features compatible with 
pulmonary sarcoidosis and a lymphocytosis on bron-
cho alveolar lavage were required to meet at least one of 
the other two criteria to be included in the study 
(appendix). In patients for whom none of these criteria 
were available, the HRCT imaging was reviewed by a 
thoracic radiologist of 25 years’ experience in the 
diagnosis of interstitial lung diseases.
Procedures
We documented age, sex, smoking status, treatment at 
the time of baseline pulmonary function tests, follow-up 
time, baseline pulmonary function tests, and presence of 
extrapulmonary symptoms. We recorded smoking status 
as “current smoker”, “ever smoker”, and “never smoker”. 
“Ever smokers” had smoked more than one cigarette a 
day for more than 1 year. Treatment was recorded at the 
time of baseline pulmonary function testing and at 
4 months follow-up (to capture patients for whom 
treatment was not instigated at ﬁ rst visit, but was begun 
soon after their ﬁ rst consultation) and consisted of one or 
a combination of corticosteroid (prednisolone) and 
immunosuppressant therapy (hydroxychloroquine, 
cyclo phosphamide, azathioprine and methotrexate). 
These data provided two separate groups for analysis 
based on the management strategy chosen—those who 
underwent observation only (intention to observe) and 
those who received treatment (intention to treat).
We measured the forced vital capacity (FVC), forced 
expiratory volume in 1 s (FEV1) and DLCO according to 
established protocols.23 The CPI, originally derived in 
idiopathic pulmonary ﬁ brosis,21 is a weighted index of 
pulmonary function that captures physiological impair-
ment due to interstitial disease but excludes impairment 
due to emphysema. We calculated this index with the 
following formula: 91·0 – (0·65 × percent predicted 
DLCO) – (0·53 × percent predicted FVC) + (0·34 × percent 
predicted FEV1) for every patient.21
The appendix shows a detailed discussion of HRCT 
scoring methods. In brief, all images were anonymised 
and two thoracic radiologists (DMH with 24 years’ 
experience and NS with 11 years’ experience) reviewed 
them independently. The entire lungs were assessed for 
the presence and extent of ﬁ brosis (deﬁ ned as criss-
crossing linear opacities [reticulation] with or without 
honeycombing [air-ﬁ lled cystic spaces with irregular 
walls deemed not to be distracted airways]), ground glass 
opaciﬁ cation, and other (deﬁ ned as patterns of disease 
not covered by ﬁ brosis or ground glass opaciﬁ cation). 
Observers also assessed the presence or absence of 
traction bronchiectasis and the presence or absence of 
emphysema. A single observer (SLFW with 8 years’ 
experience) assessed the main pulmonary artery 
diameter (MPAD) and ascending aorta diameter (AAD) 
ratio in all 503 patients (appendix).
Outcome
The primary outcome was mortality. We calculated the 
survival period starting from the date of the baseline 
pulmonary function tests to the date of death, or in the case 
of survivors the last known point of contact. Vital status was 
known for all patients at the end of the study period.
Statistical analysis
Data are given as means (SD), medians (range) or as 
proportions stated as percentages where appropriate. We 
did the statistical analyses using STATA (version 12, 
StataCorp, College Station, Texas). We made group 
comparisons using the Student’s t test, Wilcoxon rank 
sum, χ² statistics, and Fisher’s exact test where 
appropriate. We used the single determination standard 
deviation to assess interobserver agreement for con-
tinuous variables.24 We assessed interobserver agree ment 
for the presence or absence of traction bronchiectasis 
and emphysema using the weighted kappa coeﬃ  cient 
(κw) as follows: poor (κw=0–0·20), fair (κw=0·21–0·40), 
moderate (κw=0·41–0·60), good (κw=0·61–0·80), and 
excellent (κw=0·81–1·00).24
The appendix shows a detailed discussion of statistical 
methods used to derive the staging system. In brief, we 
randomly split the total patient cohort into two groups—A 
See Online for appendix
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(test cohort) and B (validation cohort). We assessed 
potential predictors of mortality, including HRCT patterns 
and the CPI, in group A. We obtained optimum thresholds, 
derived against mortality, for the strongest predictors and 
combined them to form a simple staging system. We 
externally validated the staging system in group B. Finally, 
four test observers (two radiologists and two respiratory 
physicians) assessed the staging system in groups A and B 
combined to test the models clinical applicability.
Role of the funding source
The sponsors of the study did not have any role in the 
design, data collection, analysis and interpretation, nor 
in the writing of the report. The corresponding author 
had full access to all of the data and the ﬁ nal responsibility 
to submit for publication.
Results
We identiﬁ ed 660 consecutive outpatients referred to the 
Sarcoidosis clinic at the Royal Brompton Hospital between 
Jan 1, 2000, and June 30, 2010. 59 patients were excluded 
because the diagnosis was not conﬁ rmed at multi-
disciplinary review, 89 because of no HRCT available 
within 90 days of baseline pulmonary function tests, and 
nine because of no HRCT or pulmonary function test 
evidence of pulmonary involvement. The remaining 
503 patients made up the ﬁ nal study population. Of these, 
302 had a biopsy conﬁ rmation of the presence of non-
necrotising granulomas with no alternative causes of 
granulomatous inﬂ ammation (177 with transbronchial and 
endobronchial biopsy, 12 with surgical lung biopsy, 89 with 
peripheral lymph node biopsy, 20 with skin biopsy, and 
four with liver biopsy). All but three of the remaining 
201 patients without biopsy conﬁ rmation had a clinical 
presentation consistent with pulmonary sarcoidosis, an 
HRCT, which was compatible with pulmonary sarcoidosis, 
and met at least one of the following criteria: lymphocytosis 
(>15%) on bronchoalveolar lavage (n=45), elevated serum 
angiotensin converting enzyme (ACE) level (n=157), 
demonstrable extrapulmonary features consistent with 
systemic sarcoidosis (n=57). In the three patients for whom 
none of these criteria were available, the HRCT 
appearances were deemed typical.
Group A 
(n=251)
Group B 
(n=252)
Age 52·7 (11·6) 53·0 (11·6)
Sex (female) 158 (63%) 151 (60%)
Number of deaths 49 (20%) 56 (22%)
Treated (at 4 month follow-up) 149 (59%) 179 (71%)
Race
White 138 (55%) 134 (53%)
Black, African 10 (4%) 11 (4%)
Black, Caribbean 28 (11%) 22 (9%)
Asian 26 (10%) 37 (15%)
Mixed race 9 (4%) 4 (2%)
Not stated 40 (16%) 44 (17%)
Smoking status (never, ever, current)
Never 166 (66%) 164 (66%)
Ever 76 (30%) 75 (30%)
Current 9 (4%) 13 (5%)
Mean follow up time (months) 50·5 (30·9) 49·7 (30·4)
Pulmonary function
FVC % predicted 82·4 (24·2) 81·3 (23·0)
FEV1 % predicted 72·9 (25·7) 70·7 (24·1)
DLCO % predicted 58·5 (21·4) 59·9 (20·3)
CPI 34·3 (18·4) 33·9 (17·9)
02 supplementation 19 (8%) 12 (5%)
Thin section CT
Total disease extent* 41·9 (27·0) 41·6 (26·4)
Extent of ground-glass opaciﬁ cation* 5·8 (11·9) 5·1 (11·3)
Extent of ﬁ brosis* 12·5 (16·6) 12·2 (18·3)
Other* 16·6 (0·5) 13·3 (4·2)
Emphysema (present)† 77 (31%) 80 (32%)
Traction bronchiectasis (present)† 76 (30%) 46 (18%)
Data are number of patients (%) or mean (SD). FVC=forced vital capacity. 
FEV1=forced expiratory volume in 1 s. DLCO=diﬀ using capacity of carbon monoxide. 
CPI=composite physiological index. *Percentage of total lung. †Frequency.
Table 1: Demographic data and group comparisons for group A (n=251) 
and group B (n=252), baseline pulmonary indices, and thin section CT 
variable scores
Hazard ratio 
(95% CI)
p value
Extent of ﬁ brosis 1·03 (1·01–1·04) 0·002
CPI 1·04 (1·02–1·06) <0·0001
CPI=composite physiological index. HRCT=high-resolution computed tomography.
Table 2: Mortality expressed as hazard ratios on multivariate analysis for 
HRCT patterns and pulmonary function tests including the CPI in 
sarcoidosis group A (n=251)
Figure 1: Clinical staging algorithm for stratiﬁ cation of clinical risk in 
pulmonary sarcoidosis
CPI=composite physiological index. HRCT=high-resolution computed 
tomography. MPAD/AAD=main pulmonary artery diameter to ascending aorta 
diameter ratio. 
CPI
CPI  >40 CPI ≤40
NoYes
High risk or poor prognosis Low risk or good prognosis
MPAD/AAD >1
or
extent of ﬁbrosis on HRCT >20%  
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Table 1 shows patient demographics with group 
comparisons for group A and group B. Frequencies of 
extrapulmonary manifestations of sarcoidosis, when 
present, are shown in the appendix. Mean follow-up time 
was 50·1 (SD 30·6) months (range 0·5–122·1, median 
49·8, 95% CI 38·8–58·3). Patients excluded from the ﬁ nal 
study population on the basis of no HRCT being available 
(n=89) did not diﬀ er signiﬁ cantly from the study 
population in terms of pulmonary function, follow-up 
time, or survival. The appendix shows comparisons 
between survivors and non-survivors. Four patients were 
being considered for lung transplantation at the end of the 
follow-up period. One patient died during the study while 
on a transplant list and another was on a transplant list at 
the end of the follow-up period. No patient within the 
study cohort received a transplant during the study period. 
Interobserver agreement expressed as the single 
determination standard deviation (sdSD) for the HRCT 
pattern of total disease extent was 0·9 sdSD (0–6·1), for 
ground-glass opaciﬁ cation it was 1·6 sdSD (0–9·2), and for 
ﬁ brosis 2·7 sdSD (0–14·4). Interobserver agreement for 
identifying the presence or absence of traction 
bronchiectasis and emphysema were good (κw=0·61 for 
presence and κw=0·71 for absence).
The mean size of the ascending aorta was 31·4 mm 
(SD 0·1) and that of the main pulmonary artery was 
31·3 mm (0·4), for a total of 503 patients. The mean 
MPAD/AAD ratio was 1·0 (SD 0·01). Correlation 
between the calculated MPAD/AAD category (range 0–2, 
appendix) and the observer’s estimate of the MPAD/
AAD category was excellent (r=0·94, r²=0·88, p<0·0001).
The following variables measured at baseline were 
predictive of mortality on multivariate Cox proportional 
hazards (without interaction): CPI and extent of ﬁ brosis 
on HRCT (table 2). This model was retained in 88·7% of 
bootstrap samples. To enhance the prognostic strength of 
the CPI, we generated a best-ﬁ t composite index of the 
FVC, FEV1, and DLCO, derived against mortality in 
group A (n=251). This produced an almost identical 
variable, which provided parallel prognostic information 
(appendix). An analysis of potential clinical predictors of 
mortality including the CPI was also done in the 
89 patients without imaging data, which were excluded 
from the study (appendix, expanded results). Only the 
CPI predicted mortality in this group.
We selected the CPI for threshold analysis on the basis of 
three observations—ﬁ rst, it was the strongest independent 
predictor of mortality in group A; second, a best ﬁ t 
composite of lung function derived against mortality 
oﬀ ered no advantage in predicting outcome over the CPI 
(appendix); and third, the prognostic strength of the CPI 
was robust in subgroup analyses, including treated 
patients, untreated patients, smokers, non-smokers, 
patients with and without HRCT evidence of emphysema, 
and patients with and without histological conﬁ rmation of 
diagnosis (appendix). We only did a threshold analysis after 
all continuous variables had been fully explored. We 
identiﬁ ed an optimum CPI threshold of 40 units in group A 
(HR 4·24, p<0·0001, 95% CI 2·84–6·33, c-statistic=0·72, 
bootstrap corrected 95% CI 0·69–0·82; appendix). 
We then did a multivariate analysis of HRCT patterns in 
these two subgroups (ie, CPI≤40 and CPI>40) to see 
whether HRCT data could be used to improve the 
prognostic separation provided by the CPI40. Again, we 
used a bootstrap procedure to internally validate model 
selection (ie, drawing 1000 random samples with 
replacement and selecting the model most frequently 
obtained among the 1000 samples).
First, in patients with CPI higher than 40, no HRCT 
variable was predictive of mortality. Therefore, a CPI>40 
Figure 2: Comparison of survival predicted by the sarcoidosis staging model with observed Kaplan-Meier 
estimates in the derivation cohort (group A, n=251)
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Figure 3: Comparison of survival predicted by the sarcoidosis staging model with observed Kaplan-Meier 
estimates in the test cohort (group B, n=252).
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was taken as indicative of a poor prognosis for staging 
purposes (ﬁ gure 1). Second, in patients with CPI equal or 
lower than 40, the MPAD/AAD category and extent of 
ﬁ brosis were strongly predictive of mortality on 
univariate analysis (HR 2·27, 95% CI 1·57–8·96, 
p<0·0001 for the MPAD/AAD category; HR 1·05, 
1·02–1·08, p<0·0001 for extent of ﬁ brosis). These 
variables were retained in 78·9% of the samples. We 
identiﬁ ed an optimum threshold of 20% for extent of 
ﬁ brosis in this group using the same methods of 
identiﬁ cation and discrimination used in the primary 
threshold analysis (HR 3·43, 1·94–6·06, p<0·0001, 
c-index 0·63, bootstrap corrected 95% CI 0·57–0·72). In 
this patient group, an adverse prognosis was assigned on 
the basis of MPAD/AAD category of 1 or higher (ie, 
MPAD>AAD), or extent of ﬁ brosis on HRCT higher than 
20% (ﬁ gure 1).
The ﬁ nal staging model provided a clear prognostic 
separation in group A (HR 5·71, 95% CI 3·20–13·32, 
p<0·0001, c-index 0·74, bootstrap corrected 95% CI 
0·70–0·82). We conﬁ rmed goodness of ﬁ t by comparing 
predicted survival with the empirical Kaplan-Meier 
estimates (ﬁ gure 2).
Both the extent of ﬁ brosis on HRCT (HR 1·02, 95% CI 
1·01–1·03, p<0·0001) and CPI (HR 1·04, 1·03–1·06, 
p<0·0001) were independently predictive of mortality in 
group B. The CPI40 threshold was conﬁ rmed as the 
optimum threshold (HR 4·24, 2·84–6·33, p<0·0001, 
c-index 0·70, bootstrap corrected 95% CI 0·66–0·78). 
Again, the sarcoid staging system provided the strongest 
prognostic separation of group B (HR 5·89, 2·68–10·08, 
p<0·0001, c-index 0·72, bootstrap corrected 95% CI 
0·68–0·78). Goodness of ﬁ t was conﬁ rmed by comparing 
predicted survival with the empirical Kaplan-Meier 
estimates (ﬁ gure 3).
To assess the applicability of the system in clinical 
practice, four observers (two radiologists and two 
respiratory physicians) classiﬁ ed all 503 patients (group A 
and B combined) as having a good or poor prognosis on 
the basis of the sarcoid staging system shown in ﬁ gure 1. 
Interobserver agreement between radiologists and 
physicians was excellent (κw=0·70). The sarcoid staging 
system was strongly predictive for all observers with 
(HR 4·91–5·45; table 3).
The sarcoid staging system provided sharp prognostic 
discrimination in the following subgroups: treated 
patients, untreated patients, smokers, non-smokers, 
patients with and without HRCT evidence of emphysema, 
and patients with and without histological conﬁ rmation 
of diagnosis, selected from group A and group B 
combined (n=503, table 4).
Discussion
We describe an easily applicable staging system for 
patients with pulmonary sarcoidosis, integrating the CPI 
and two HRCT variables, which provides rapid 
identiﬁ cation of patients at high clinical risk. The staging 
system was derived and rigorously tested in a large cohort 
of patients with conﬁ rmed pulmonary sarcoidosis before 
being externally validated in a new patient population. 
Additionally, two radiologists and two respiratory 
physicians subsequently veriﬁ ed the clinical applicability 
of the staging system by applying it to the combined 
cohorts. Further, we have shown that the staging system 
retained its prognostic strength in patient subgroups 
including: treated and untreated patients, smokers and 
non-smokers, patients with and without HRCT evidence 
of emphysema, and patients with and without histological 
conﬁ rmation of the diagnosis of sarcoidosis (panel).
Our sarcoidosis clinic is a regional and national 
referral centre for patients with pulmonary sarcoidosis. 
A unifying feature of our population is that patients 
referred to our centre are not straightforward—either 
the referrer perceives a diﬃ  culty managing the disease, 
or the patient has had a signiﬁ cant loss of quality of life 
despite standard therapies. Additionally, because of 
increased patient involvement in management 
decisions, in some cases, the referral is driven by the 
patient. For this reason it is diﬃ  cult to standardise and 
document the referral criteria. Recent prognostic 
assessment in pulmonary sarcoidosis has been largely 
conﬁ ned to transplantation populations, which are 
inherently biased towards endstage disease.17,19 In 
unselected patients with sarcoidosis, mortality is 
arguably too low for survival analyses to be powered. By 
contrast, the higher mortality expected in referral centre 
populations,14 allows the derivation and testing of a 
prognostic algorithm that is anchored to survival, as in 
the present study. Our ﬁ ndings apply to the important 
Hazard ratio p value
Radiologist 1 5·45 (3·31–8·99) <0·0001
Radiologist 2 5·28 (3·26–8·53) <0·0001
Physician 1 5·36 (3·21–8·93) <0·0001
Physician 2 4·91 (3·18–8·23) <0·0001
Table 3: Mortality expressed as hazard ratios on univariate analysis for 
the entire cohort (n=503), in relation to the sarcoidosis staging model, 
categorised by radiologists (n=2) and physicians (n=2)
Number Hazard ratio p value
Treated (intention to treat) 328 6·20 (3·13–12·27) 0·001
Not treated (intention to 
observe)
175 6·19 (2·44–10·64) <0·0001
Smoker 172 3·62 (1·68–7·79) 0·001
Non smoker 331 9·76 (4·44–15·27) <0·0001
Emphysema 149 2·85 (1·35–6·01) 0·006
No emphysema 354 10·61 (4·80–20·41) <0·0001
Biopsy 302 5·89 (2·99–11·57) <0·0001
No biopsy 201 7·74 (2·98–16·07) <0·0001
Table 4: Mortality expressed as hazard ratios on univariate analysis for 
the sarcoidosis staging model in various patient subgroups within the 
entire cohort (group A and group B, n=503)
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subset of patients in whom pulmonary disease is more 
severe and often diﬃ  cult to manage; in these patients, 
assessment of prognosis is especially valuable. The 
development of a staging system against mortality in a 
more general population with sarcoidosis with prolonged 
follow-up, although ideal in principle, is likely to be an 
unrealistic goal, requiring the recruitment of a huge 
population of patients with sarcoidosis outside of referral 
centres. Importantly, our prognostic algorithm was 
constructed from tests that are appropriate in the 
investigation of pulmonary involvement in general and 
can, thus, be readily applied to patients with overt 
pulmonary sarcoidosis in less selected populations.
Outcome in pulmonary sarcoidosis is largely inﬂ uenced 
by two separate pathological processes—interstitial ﬁ brosis 
and pulmonary arterial hypertension. The latter is 
increasingly being recognised as relatively frequent in 
sarcoidosis.17,25 In unselected cohorts about 5–6% of 
patients with pulmonary sarcoidosis have pulmonary 
arterial hypertension at rest16,26 and as many as 43% of 
patients with normal resting pulmonary artery pressures 
develop pulmonary arterial hypertension during 
exercise.26–28 Moreover, pulmonary arterial hypertension is 
found in up to 47% of patients with sarcoidosis with 
dyspnoea out of proportion to their pulmonary function 
deﬁ cit.20 Importantly, pulmonary arterial hypertension is 
not conﬁ ned to those with advanced ﬁ brotic disease—
about half of patients with pulmonary arterial hypertension 
have no radiographic evidence of ﬁ brosis.18,29 In some cases 
of pulmonary hypertension, increases in the capillary 
blood pool might result in a normal or elevated DLCO. 
However, as pulmonary hypertension in patients with 
sarcoidosis is, in most cases, a precapillary phenomenon, 
engorgement of the pulmonary microvasculature does not 
usually occur, making elevations of the DLCO unlikely. As 
an example, it is known that in patients with systemic 
sclerosis related pulmonary hypertension (which is also a 
precapillary phenomenon), pulmonary capillary blood 
volume does not increase and consequently no increase in 
DLCO is noted. As the CPI incorporates pulmonary 
function indices that capture the physiological eﬀ ect of 
vasculopathy (DLCO) as well as those that reﬂ ect restrictive 
interstitial physiology (FEV1 and FVC), we formed an a 
priori hypothesis that the CPI would be a strong predictor 
of outcome in these patients. This hypothesis was tested 
and validated and reinforced by two ﬁ ndings. First, a 
composite of lung function derived against mortality and 
the CPI were collinear and, second, the CPI remained a 
strong predictor of mortality in various patient subgroups.
In view of the importance of pulmonary arterial 
hypertension in determining mortality in sarcoidosis,5 
the vascular measurement used in our study warrants 
examination. CT signs of pulmonary arterial hypertension 
have been investigated extensively in the setting of 
various diﬀ use lung diseases including idiopathic 
pulmonary ﬁ brosis,30–33 but less is known about the 
accuracy of these signs in pulmonary sarcoidosis. The 
ratio of MPAD/AAD has been shown to predict 
pulmonary arterial hypertension in patients with 
interstitial lung disease more reliably than the MPAD 
alone.32 This ﬁ nding has been extended to include patients 
with ﬁ brotic lung disease.33 In our study, the MPAD/AAD 
category was predictive of mortality independently of all 
other HRCT patterns, suggesting that in sarcoidosis, the 
MPAD/AAD ratio might capture the prognostic eﬀ ect of 
an underlying vasculopathy. Furthermore, visual 
estimates of the MPAD/AAD ratio correlate closely with 
electronic calliper measurements enhancing the clinical 
use of this ﬁ nding. Although it might be, that other 
investigations could be included in the staging system, 
such as echocardiography34 or right heart catheterisation,35 
a central aim of this model was to provide clinicians with 
a prognostic method that can be applied easily to most 
patients; only a few patients with pulmonary sarcoidosis 
undergo right heart catheterisation.
Management decisions in diﬀ use lung disease are often 
dichotomous, such as the decision to treat when disease 
is likely to be responsive versus the decision not to treat in 
inexorably progressive disease. Clinicoradiological and 
physiological scores and multivariate systems previously 
described in other diﬀ use lung diseases36,37 are usually 
continuous and for this reason might not be easily applied 
to these decisions. This provides the rationale for staging 
patients by classifying them into one of two prognostically 
distinct groups and is an approach already used in the 
setting of systemic sclerosis related interstitial lung 
disease.38 By integrating the CPI with CT data, we have 
devised a staging system, which captured the most deaths 
Panel: Research in context
Systematic review
We did a PubMed search on Oct 1, 2013, using the search terms “pulmonary sarcoidosis and 
prognosis” for the period between Jan 1, 1990, and Oct 1, 2013. Our search was restricted to 
publications that were written in English. We identiﬁ ed 12 key publications1,5–8,10,12,13,16,17,19,20 
that were pertinent to our study. All of these studies investigated diﬀ erent methods for 
predicting prognosis in pulmonary sarcoidosis and their eﬃ  cacy. Additionally, several 
reported on the prevalence and prognostic signiﬁ cance of pulmonary arterial hypertension 
in the setting of pulmonary sarcoidosis. We could not ﬁ nd any study that reported on 
staging of patients with pulmonary sarcoidosis with integrated clinical and radiological data.
Interpretation
Attempts to devise a reliable prognostic method for sarcoidosis, until now, have been largely 
unsuccessful and this has represented a substantial obstacle to the development of consensus 
management and treatment recommendations for this disease. Our study describes an easily 
applied and powerful staging system that identiﬁ es patients with pulmonary sarcoidosis who 
are at high clinical risk. This staging system was constructed with the composite physiological 
index and two HRCT variables in a large cohort of patients with pulmonary sarcoidosis. Two 
radiologists and two respiratory physicians found the system easy to use. Although this 
staging system was derived in a tertiary referral centre population of patients with pulmonary 
sarcoidosis, it was constructed with tests that are routinely done in most patients and can 
therefore, in principle, be applied to patients with pulmonary sarcoidosis in less selected 
populations. Ideally, this staging system should undergo further assessment in patients with 
less severe disease or at other less specialised centres. 
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when tested prospectively in a large cohort of patients 
with pulmonary sarcoidosis. To our knowledge, no other 
prognostic index in pulmonary sarcoidosis provides such 
a sharp separation of patients into groups with a low and 
high risk of mortality respectively.
The eﬀ ectiveness of HRCT lies in its ability to capture 
patients initially classiﬁ ed as having a good prognosis 
using the CPI40 threshold, and reclassifying them based 
on either a large main pulmonary artery (vascular 
disease), or presence of ﬁ brosis (interstitial disease). It is 
conceivable that the CPI might be a less sensitive 
predictor of mortality in patients with a low DLCO (due 
to pulmonary arterial hypertension) but quite preserved 
spirometry, which explains why some patients with a 
poor prognosis have a low CPI. This notion highlights 
the important complimentary role of HRCT in the 
assessment of patients with pulmonary sarcoidosis.
Our study used a relatively simple approach to HRCT 
pattern evaluation. The choice of patterns was based on 
three criteria: (1) the pattern had to be frequently present 
and extensive enough to identify with conﬁ dence, (2) the 
pattern had to be readily recognisable for both non-
experts and experts, and (3) the pattern had to be a 
plausible prognostic determinant. The prognostic eﬀ ect 
of so-called diﬃ  cult to assess patterns, is unlikely to be 
useful in clinical practice. For these reasons, the readily 
recognised patterns of ground glass opaciﬁ cation and 
ﬁ brosis, as well as traction bronchiectasis were selected. 
The relatively high levels of interobserver agreement seen 
in the current study for these patterns vindicated these 
choices. It should be pointed out, that a characteristic 
feature of pulmonary sarcoidosis is that its HRCT 
presentation is very variable making it diﬃ  cult to 
standardise its quantiﬁ cation on HRCT.
Patient treatment was documented at baseline and at 
4 months’ follow-up and therapeutic status was analysed 
according to whether or not treatment was deemed 
warranted at presentation. This coarse distinction was 
necessary as the choice, timing, and duration of 
treatment varied widely during follow-up, and could not 
realistically be accounted for in the analysis. We therefore 
provided separate statements for two patient subgroups: 
intention to treat (when treatment was introduced or 
continued at presentation) and intention to observe, an 
approach, also used in the development of prognostic 
staging systems in the setting of systemic sclerosis.38 In 
this analysis, the staging system provided equal 
prognostic information regardless of whether patients 
were treated or observed (table 4).
Not all cases included in the study had conﬁ rmation of 
diagnosis by biopsy. When patients are involved in 
decisions on whether to biopsy, or where pulmonary 
impairment is too severe, the number of cases with a 
histological conﬁ rmation of diagnosis will necessarily be 
less. Furthermore, it has been argued that there is no 
diagnostic gold standard in sarcoidosis.39 The diagnosis is 
often made after assimilation of all data available and 
possible alternatives have been excluded.40 A strength of 
our study is the rigorous approach taken to patient 
selection when conﬁ rmation by biopsy was not available. 
At the outset, cases with or without a conﬁ rmed diagnosis 
by biopsy presented with clinical and HRCT features 
compatible with pulmonary sarcoidosis. Those without 
conﬁ rmation by biopsy were required to meet at least one 
more diagnostic criterion. Additionally, steps were taken to 
eliminate possible contamination of the population with 
cases of chronic hypersensitivity pneumonitis by ensuring 
that those with a lymphocytosis on bronchoalveolar lavage 
also met one of the other diagnostic criteria. We noted no 
survival diﬀ erence between patients with conﬁ rmation by 
biopsy of their diagnosis and those for whom the diagnosis 
was based on the diagnostic criteria described above.
We used an all-cause mortality endpoint rather than 
attempting to analyse only patients who died directly as 
a result of their primary pulmonary disease. Just as 
intention to treat is considered the gold standard study 
design in treatment trials, we used the intention to 
prognosticate approach in the present study to maintain 
clinical applicability. When a staging system is applied 
in clinical practice, it is never known whether an 
individual patient might eventually die from an 
unrelated cause. Thus, the utility of a prognostic system 
in separating survivors from non-survivors must be 
tested against all-cause mortality. This approach has also 
been recommended in the setting of idiopathic 
pulmonary ﬁ brosis for which all-cause mortality is 
regarded the most easily interpreted mortality-related 
endpoint in phase 3 clinical trials.41 Furthermore, there 
are inherent diﬃ  culties separating respiratory and non-
respiratory deaths. A cardiac event for example, might 
ultimately result in death, but might be triggered by 
hypoxia caused by pulmonary disease. Lastly, our study 
was retrospective in design and drew its study population 
from one centre. Although we used a split sample 
method to validate the system, ideally it should be tested 
in a separate large cohort of patients with pulmonary 
sarcoidosis, garnered from another centre.
In conclusion, by integrating the CPI with HRCT 
measures of the pulmonary vasculature and interstitial 
disease, we propose an easily applied staging system that 
identiﬁ es patients at high clinical risk. This system has 
been rigorously assessed using internal and external 
validation and subsequent testing for clinical applicability 
by two radiologists and two physicians. In principle, this 
model might be used by the clinician as a simple but 
powerful prognostic method for risk stratiﬁ cation of 
patients in routine clinical practice and the enrolment of 
patients in clinical trials.
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